Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2021-2026

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2021-2026

According to this latest study, the 2021 growth of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy will have significant change from previous year. By the most conservative estimates of global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ million in 2020. Over the next five years the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market will register a % CAGR in terms of revenue, the global market size will reach US$ million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021 in Section 2.3; and forecast to 2026 in section 10.7.
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 10.8.
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.


*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2016-2026
2.1.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region 2020 VS 2021 VS 2026
2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
2.2.1 Single-stranded AAV (ssAAV)
2.2.2 Single-stranded AAV (ssAAV)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
2.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type
2.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2016-2021)
2.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
2.4.1 Hemophilia
2.4.2 Ophthalmology
2.4.3 Lysosomal Storage Disorders
2.4.4 Neurological Disorders
2.4.5 Others
2.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
2.5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application
2.5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2016-2021)
3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Players
3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Players
3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2019-2021E)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2019-2021E)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Regions
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions (2016-2021)
4.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2016-2021)
4.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2016-2021)
4.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2016-2021)
4.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2016-2021)
5 Americas
5.1 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2016-2021)
5.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
5.3 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2016-2021)
6.2 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
6.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country (2016-2021)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region (2016-2021)
8.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
8.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2021-2026)
10.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2021-2026)
10.1.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Countries (2021-2026)
10.2.1 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.2 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.3 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.4 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2021-2026)
10.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.3 Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.4 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.6 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2021-2026)
10.4.1 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.2 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.3 UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.4 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2021-2026)
10.5.1 Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.2 South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.4 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.5 GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Type (2021-2026)
10.7 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Application (2021-2026)
11 Key Players Analysis
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Information
11.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.1.4 BioMarin Pharmaceutical Main Business Overview
11.1.5 BioMarin Pharmaceutical Latest Developments
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Information
11.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.2.4 Sangamo Therapeutics Main Business Overview
11.2.5 Sangamo Therapeutics Latest Developments
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Information
11.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.3.4 Amicus Therapeutics Main Business Overview
11.3.5 Amicus Therapeutics Latest Developments
11.4 Roche
11.4.1 Roche Company Information
11.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.4.4 Roche Main Business Overview
11.4.5 Roche Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 NightstaRx
11.6.1 NightstaRx Company Information
11.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.6.4 NightstaRx Main Business Overview
11.6.5 NightstaRx Latest Developments
11.7 MeiraGTx
11.7.1 MeiraGTx Company Information
11.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.7.4 MeiraGTx Main Business Overview
11.7.5 MeiraGTx Latest Developments
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Information
11.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.8.4 Sarepta Therapeutics Main Business Overview
11.8.5 Sarepta Therapeutics Latest Developments
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Information
11.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.9.4 Neurocrine Biosciences Main Business Overview
11.9.5 Neurocrine Biosciences Latest Developments
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Information
11.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.10.4 Voyager Therapeutics Main Business Overview
11.10.5 Voyager Therapeutics Latest Developments
11. Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Information
11.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2021)
11.11.4 Asklepios Biopharmaceutical Main Business Overview
11.11.5 Asklepios Biopharmaceutical Latest Developments
12 Research Findings and Conclusion

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook